75 results
8-K
EX-10.1
NVRO
Nevro Corp
1 Dec 23
Nevro Announces Acquisition of Vyrsa™ Technologies
6:07am
;
(c) in connection with any clinical, preclinical, safety or other studies or tests being conducted by (or on behalf of) the Borrower or any of its … and Development Activities (i) the failure of any clinical, pre-clinical, safety or other required trial, study or test to be conducted in material compliance
8-K
EX-2.1
NVRO
Nevro Corp
1 Dec 23
Nevro Announces Acquisition of Vyrsa™ Technologies
6:07am
of employees, working conditions, meal and break periods, privacy, health and safety, workers’ compensation, leaves of absence and unemployment … withdrawals, “dear doctor” letters, safety alerts or other notice of Action relating to an alleged lack of safety, efficacy, or regulatory compliance
8-K
EX-99.1
s0va0dpecfb2sr9l0a5
5 May 20
Nevro Reports First Quarter 2020 Financial Results
4:16pm
8-K
EX-1.1
qomrdrszejbe0dx
7 Apr 20
Entry into a Material Definitive Agreement
7:00am
8-K
EX-1.2
sf5rv05hio tw
7 Apr 20
Entry into a Material Definitive Agreement
7:00am